Standard treatment with bevacizumab as targeted therapy in cervical cancer
Rev. invest. clín
; 72(4): 213-218, Jul.-Aug. 2020.
Artigo
em Inglês
| LILACS
| ID: biblio-1251858
Biblioteca responsável:
BR1.1
ABSTRACT
ABSTRACT Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Neoplasias do Colo do Útero
/
Bevacizumab
Tipo de estudo:
Estudo prognóstico
Aspecto:
Preferência do paciente
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Rev. invest. clín
Assunto da revista:
Medicina
Ano de publicação:
2020
Tipo de documento:
Artigo
País de afiliação:
Dinamarca
/
Índia
/
México
Instituição/País de afiliação:
Centro Médico Nacional 20 de Noviembre/MX
/
Instituto Nacional de Cancerología/MX
/
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado/MX
